High-risk mucosal types of human papillomavirus (HPV) cause anogenital and oropharyngeal cancers, whereas cutaneous types (e.g. HPV8 and 77) are suspected to be involved in non-melanoma skin cancer. The antibody response to HPVs is a key determinant of protective immunity, but not all infected individuals seroconvert. Genetic variability of the host may have large impact on seroconversion. A previous genome-wide association study (GWAS) has identified a susceptibility locus (rs41270488) for HPV8 seropositivity within the major histocompatibility complex (MHC) region. To further study this locus, we imputed alleles at classical leukocyte antigen (HLA) loci using HLA*IMP:02 with a reference panel from the HapMap Project and the 1958 Birth Cohort, and conducted an integrated analysis among 4811 central European subjects to assess the contribution of classical HLA alleles and gene copy number variation (CNV) at the hypervariable DRB locus within the MHC region to HPV seropositivity at both the individual HPV type level and the phylogenetic species level. Our study provides evidence that the association noted between rs41270488 and HPV8 seropositivity is driven by two independent variants, namely DQB1*0301 [odds ratio (OR) = 1.51, 95% confidence interval (CI) = 1.36-1.68, P = 1.0 × 10(-14)] and DRB1*1101 (OR = 1.89, 95%CI = 1.57-2.28, P = 1.5 × 10(-11)) within the HLA class II region. Additionally, we identified two correlated alleles DRB1*0701 (OR = 1.67, 95%CI = 1.41-1.98, P = 2.6 × 10(-9)) and DQA1*0201 (OR = 1.67, 95%CI = 1.38-1.93, P = 1.7 × 10(-8)), to be associated with HPV77 seropositivity. Comparable results were observed through imputation using SNP2HLA with another reference panel from the Type 1 diabetes Genetics Consortium. This study provides support for an important role of HLA class II alleles in antibody response to HPV infection.

Centre D'innovation Génome Québec et Université McGill Montréal Canada

Department of Cancer Epidemiology and Genetics Masaryk Memorial Cancer Institute Brno Czech Republic

Department of Cancer Epidemiology and Prevention M Sklodowska Curie Memorial Cancer Center and Institute of Oncology Warsaw Poland

Department of Epidemiology Institute of Occupational Medicine Lodz Poland

Department of Immunology Genetics and Pathology Science for Life Laboratory Uppsala Uppsala University Uppsala Sweden

Department of Neurosurgery 1st Affiliated Hospital of Nanjing Medical University Nanjing China

Department of Neurosurgery Huashan Hospital Shanghai Medical School Fudan University Shanghai China

Genetic Cancer Susceptibility Group International Agency for Research on Cancer Lyon France

Genetic Epidemiology Group

Infections and Cancer Epidemiology Group Division of Genome Modifications and Carcinogenesis

Institute of Carcinogenesis Cancer Research Centre Moscow Russia

Institute of Hygiene and Epidemiology 1st Faculty of Medicine Charles University Prague Czech Republic

Ministry of Education and Shanghai Key Laboratory of Children's Environmental Health Xinhua Hospital Shanghai Jiao Tong University School of Medicine Shanghai China Department of Immunology Genetics and Pathology Science for Life Laboratory Uppsala Uppsala University Uppsala Sweden

Mount Sinai Hospital Icahn Medical Institute New York USA and

National Institute of Environmental Health Budapest Hungary

Palacky University Olomouc Czech Republic

Regional Authority of Public Health Banská Bystrica Slovakia

St Mary General and Esophageal Surgery Clinic Carol Davila University of Medicine and Pharmacy Bucharest Romania

Virus Host Interactions of Polyoma and Papilloma Viruses Group Division of Genome Modifications and Carcinogenesis German Cancer Research Center Heidelberg Germany

000      

00000naa a2200000 a 4500

001      

bmc16000353

003      

CZ-PrNML

005      

20160125123901.0

007      

ta

008      

160108s2015 enk f 000 0|eng||

009      

AR

024    7_

$a 10.1093/hmg/ddv015 $2 doi

035    __

$a (PubMed)25616963

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a enk

100    1_

$a Chen, Dan $u Ministry of Education and Shanghai Key Laboratory of Children's Environmental Health, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Department of Immunology, Genetics and Pathology, Science for Life Laboratory Uppsala, Uppsala University, Uppsala, Sweden, simpledandan1981@163.com dan.chen@igp.uu.se brennanp@iarc.fr.

245    12

$a A systematic investigation of the contribution of genetic variation within the MHC region to HPV seropositivity / $c D. Chen, V. Gaborieau, Y. Zhao, A. Chabrier, H. Wang, T. Waterboer, D. Zaridze, J. Lissowska, P. Rudnai, E. Fabianova, V. Bencko, V. Janout, L. Foretova, IN. Mates, N. Szeszenia-Dabrowska, P. Boffetta, M. Pawlita, M. Lathrop, U. Gyllensten, P. Brennan, JD. McKay,

520    9_

$a High-risk mucosal types of human papillomavirus (HPV) cause anogenital and oropharyngeal cancers, whereas cutaneous types (e.g. HPV8 and 77) are suspected to be involved in non-melanoma skin cancer. The antibody response to HPVs is a key determinant of protective immunity, but not all infected individuals seroconvert. Genetic variability of the host may have large impact on seroconversion. A previous genome-wide association study (GWAS) has identified a susceptibility locus (rs41270488) for HPV8 seropositivity within the major histocompatibility complex (MHC) region. To further study this locus, we imputed alleles at classical leukocyte antigen (HLA) loci using HLA*IMP:02 with a reference panel from the HapMap Project and the 1958 Birth Cohort, and conducted an integrated analysis among 4811 central European subjects to assess the contribution of classical HLA alleles and gene copy number variation (CNV) at the hypervariable DRB locus within the MHC region to HPV seropositivity at both the individual HPV type level and the phylogenetic species level. Our study provides evidence that the association noted between rs41270488 and HPV8 seropositivity is driven by two independent variants, namely DQB1*0301 [odds ratio (OR) = 1.51, 95% confidence interval (CI) = 1.36-1.68, P = 1.0 × 10(-14)] and DRB1*1101 (OR = 1.89, 95%CI = 1.57-2.28, P = 1.5 × 10(-11)) within the HLA class II region. Additionally, we identified two correlated alleles DRB1*0701 (OR = 1.67, 95%CI = 1.41-1.98, P = 2.6 × 10(-9)) and DQA1*0201 (OR = 1.67, 95%CI = 1.38-1.93, P = 1.7 × 10(-8)), to be associated with HPV77 seropositivity. Comparable results were observed through imputation using SNP2HLA with another reference panel from the Type 1 diabetes Genetics Consortium. This study provides support for an important role of HLA class II alleles in antibody response to HPV infection.

650    12

$a alely $7 D000483

650    _2

$a studie případů a kontrol $7 D016022

650    _2

$a ženské pohlaví $7 D005260

650    12

$a genetická predispozice k nemoci $7 D020022

650    12

$a genetická variace $7 D014644

650    _2

$a HLA antigeny $x genetika $7 D006680

650    _2

$a haplotypy $7 D006239

650    _2

$a lidé $7 D006801

650    _2

$a vazebná nerovnováha $7 D015810

650    _2

$a hlavní histokompatibilní komplex $x genetika $7 D008285

650    _2

$a mužské pohlaví $7 D008297

650    _2

$a odds ratio $7 D016017

650    _2

$a Papillomaviridae $x klasifikace $x genetika $7 D027383

650    _2

$a infekce papilomavirem $x genetika $x virologie $7 D030361

650    _2

$a jednonukleotidový polymorfismus $7 D020641

655    _2

$a časopisecké články $7 D016428

655    _2

$a multicentrická studie $7 D016448

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Gaborieau, Valérie $u Genetic Epidemiology Group.

700    1_

$a Zhao, Yao $u Department of Neurosurgery, Huashan Hospital, Shanghai Medical School, Fudan University, Shanghai, China.

700    1_

$a Chabrier, Amélie $u Genetic Cancer Susceptibility Group, International Agency for Research on Cancer (IARC), Lyon, France.

700    1_

$a Wang, Huibo $u Department of Neurosurgery, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

700    1_

$a Waterboer, Tim $u Infections and Cancer Epidemiology Group, Division of Genome Modifications and Carcinogenesis.

700    1_

$a Zaridze, David $u Institute of Carcinogenesis, Cancer Research Centre, Moscow, Russia.

700    1_

$a Lissowska, Jolanta $u Department of Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.

700    1_

$a Rudnai, Peter $u National Institute of Environmental Health, Budapest, Hungary.

700    1_

$a Fabianova, Eleonora $u Regional Authority of Public Health, Banská Bystrica, Slovakia.

700    1_

$a Bencko, Vladimir $u Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.

700    1_

$a Janout, Vladimir $u Palacky University, Olomouc, Czech Republic.

700    1_

$a Foretova, Lenka $u Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic.

700    1_

$a Mates, Ioan Nicolae $u St Mary General and Esophageal Surgery Clinic, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.

700    1_

$a Szeszenia-Dabrowska, Neonila $u Department of Epidemiology, Institute of Occupational Medicine, Lodz, Poland.

700    1_

$a Boffetta, Paolo $u Mount Sinai Hospital, Icahn Medical Institute, New York, USA and.

700    1_

$a Pawlita, Michael $u Virus-Host Interactions of Polyoma and Papilloma Viruses Group, Division of Genome Modifications and Carcinogenesis, German Cancer Research Center (DKFZ), Heidelberg, Germany.

700    1_

$a Lathrop, Mark $u Centre D'innovation Génome Québec et Université McGill, Montréal, Canada.

700    1_

$a Gyllensten, Ulf $u Department of Immunology, Genetics and Pathology, Science for Life Laboratory Uppsala, Uppsala University, Uppsala, Sweden.

700    1_

$a Brennan, Paul $u Genetic Epidemiology Group, simpledandan1981@163.com dan.chen@igp.uu.se brennanp@iarc.fr.

700    1_

$a McKay, James D $u Genetic Cancer Susceptibility Group, International Agency for Research on Cancer (IARC), Lyon, France.

773    0_

$w MED00002077 $t Human molecular genetics $x 1460-2083 $g Roč. 24, č. 9 (2015), s. 2681-8

856    41

$u https://pubmed.ncbi.nlm.nih.gov/25616963 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y a $z 0

990    __

$a 20160108 $b ABA008

991    __

$a 20160125124024 $b ABA008

999    __

$a ok $b bmc $g 1102634 $s 924559

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2015 $b 24 $c 9 $d 2681-8 $e 20150123 $i 1460-2083 $m Human molecular genetics $n Hum Mol Genet $x MED00002077

LZP    __

$a Pubmed-20160108